ADAI Provides Resources to Treat Opioid Use Disorder

Jan 14, 2025 - The Clinical Trials Network Node of the UW Addictions, Drug & Alcohol Institute offers short videos and factsheets for providers. Buprenorphine is one of three medications (along with methadone and naltrexone) approved for use to treat opioid use disorder. It is available as a film or tablet, and more recently as two long-acting extended-release injectables. Clinicians with familiarity using injectables shared their real-world experiences and lessons learned as part of the June 13, 2024 UW Psychiatry & Addiction Case Conference (UW-PACC).  The content was used to produce short clinician-focused videos, available here.